GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Long-Term Debt

Roquefort Therapeutics (LSE:ROQ) Long-Term Debt : £0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Long-Term Debt?

Roquefort Therapeutics's Long-Term Debt for the quarter that ended in Dec. 2023 was £0.00 Mil.


Roquefort Therapeutics Long-Term Debt Historical Data

The historical data trend for Roquefort Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Long-Term Debt Chart

Roquefort Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Long-Term Debt
- - -

Roquefort Therapeutics Semi-Annual Data
Jun21 Jun22 Dec22 Jun23 Dec23
Long-Term Debt - - - - -

Roquefort Therapeutics  (LSE:ROQ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Roquefort Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Roquefort Therapeutics (LSE:ROQ) Business Description

Traded in Other Exchanges
Address
85 Great Portland Street, First Floor, London, GBR, W1W 7LT
Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines